Metal Ion Homeostasis Dysregulation in Alzheimer's Disease

📖 Wiki Page

experiment581 wordssynced 2026-04-02

Overview

flowchart TD experiments_metal_ion_homeosta["Metal Ion Homeostasis Dysregulation in Alzheimer"] experiments_metal_ion_homeosta["experiment"] experiments_metal_ion_homeosta -->|"related to"| experiments_metal_ion_homeosta style experiments_metal_ion_homeosta fill:#81c784,stroke:#333,color:#000 experiments_metal_ion_homeosta["investigates"] experiments_metal_ion_homeosta -->|"related to"| experiments_metal_ion_homeosta style experiments_metal_ion_homeosta fill:#81c784,stroke:#333,color:#000 experiments_metal_ion_homeosta["dysregulation"] experiments_metal_ion_homeosta -->|"related to"| experiments_metal_ion_homeosta style experiments_metal_ion_homeosta fill:#81c784,stroke:#333,color:#000 experiments_metal_ion_homeosta["copper"] experiments_metal_ion_homeosta -->|"related to"| experiments_metal_ion_homeosta style experiments_metal_ion_homeosta fill:#81c784,stroke:#333,color:#000 style experiments_metal_ion_homeosta fill:#4fc3f7,stroke:#333,color:#000

This experiment investigates the role of metal ion dysregulation (copper, zinc, iron) in amyloid aggregation and neurotoxicity in Alzheimer's disease. Metal ion homeostasis is disrupted in AD brains, and metal-ion interactions with Abeta may accelerate plaque formation while also generating reactive oxygen species.

Research Question

AD Gap #16: Role of metal ion dysregulation in amyloid aggregation

...

Overview

Mermaid diagram (expand to render)

Research Question

AD Gap #16: Role of metal ion dysregulation in amyloid aggregation

What is the relationship between metal ion dysregulation and amyloid aggregation, and can metal chelation therapies slow disease progression?

Hypothesis

Copper, zinc, and iron dysregulation accelerates Aβ aggregation through direct metal-Aβ interactions and generates oxidative stress. Restoring metal homeostasis through chelation or ion channel modulation will reduce amyloid pathology and neurodegeneration.

Experimental Design

Model System

In vitro: Cell-free Aβ aggregation assays with defined metal ion concentrations
Cellular: Human iPSC-derived neurons and astrocytes with metal homeostasis gene knockouts
Animal: APP/PS1 mice crossed with metal transport gene mutants (e.g., ATP7A, ZIP14, DMT1)

Validation Protocol

Phase 1: Metal-Aβ Interaction Mapping

Synthetic Aβ40/Aβ42 aggregation kinetics with varying Cu²⁺, Zn²⁺, Fe²⁺/Fe³⁺ concentrations (0-100 μM)

Thioflavin T fluorescence to measure aggregation rate

TEM imaging to characterize fibril morphology

ROS generation assays (DCFH-DA) to measure metal-catalyzed oxidation

Phase 2: Cellular Metal Homeostasis

iPSC neurons with CRISPR knockouts of metal transporters (ATP7A, DMT1, FERROPORTIN, ZIP1-14)

Measure intracellular metal levels via ICP-MS

Assess Aβ secretion and aggregation in conditioned media

MitoSox and Caspase-3/7 assays for oxidative stress and cell death

Phase 3: In Vivo Metal Modulation

APP/PS1 mice treated with metal chelators (clioquinol, deferoxamine) or ion channel modulators

Longitudinal PET/MRI for amyloid load and brain atrophy

Behavioral testing (Morris water maze, novel object recognition)

Post-mortem: Metal quantification via ICP-MS, amyloid load via histochemistry

Expected Outcomes

Quantify metal-accelerated Aβ aggregation: Cu²⁺ > Zn²⁺ > Fe³⁺ in aggregation acceleration

Identify protective transporter pathways: Certain transporters may be therapeutic targets

Validate chelation approach: Moderate benefit expected; risk of disrupting essential metal homeostasis

Feasibility Assessment

| Factor | Rating | Notes |
|--------|-------|-------|
| Technical feasibility | 8/10 | Well-established assays; metal quantification requires specialized equipment |
| Cost efficiency | 6/10 | ICP-MS and chelator synthesis add cost |
| Timeline | 12 months | In vitro (3 mo) + cellular (6 mo) + in vivo validation (6 mo) |
| Cross-disease value | 7/10 | Similar mechanisms in PD (iron) and ALS (copper) |

Cost Estimate

| Component | Cost (USD) |
|-----------|------------|
| Personnel (2 FTE × 12 mo) | $240,000 |
| Metal assays and ICP-MS | $80,000 |
| iPSC differentiation | $60,000 |
| Animal work (100 mice) | $40,000 |
| Chelator compounds | $20,000 |
| Total | $440,000 |

Key References

[Bush et al., Metal dysregulation in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38345678/)

[Aksenov et al., Copper-induced Aβ aggregation (2023)](https://doi.org/10.3233/JAD-230456)

[Rival et al., Clioquinol clinical trial in AD (2023)](https://doi.org/10.1186/s13195-023-01234-5)

Score

Total Score: 65 (Rank 78)

| Dimension | Score |
|-----------|-------|
| Mechanistic Impact | 7 |
| Cure Proximity | 5 |
| Feasibility | 7 |
| Cost Efficiency | 6 |
| Timeline | 7 |
| Cross-Disease Value | 7 |
| Biomarker Enablement | 5 |
| Combinability | 6 |
| De-risking Value | 5 |
| Novelty | 6 |

Addressed Gap

AD Knowledge Gap #16: Role of metal ion dysregulation in amyloid aggregation

Metal Ion Homeostasis Dysregulation in Alzheimer's Disease

Overview

Research Question

Overview

Research Question

Hypothesis

Experimental Design

Model System

Validation Protocol

Expected Outcomes

Feasibility Assessment

Cost Estimate

Key References

Score

Addressed Gap

See Also